Your browser doesn't support javascript.
loading
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
Pietrantonio, Filippo; Loupakis, Fotios; Randon, Giovanni; Raimondi, Alessandra; Salati, Massimiliano; Trapani, Dario; Pagani, Filippo; Depetris, Ilaria; Maddalena, Giulia; Morano, Federica; Corallo, Salvatore; Prisciandaro, Michele; Corti, Francesca; Guarini, Vincenzo; Bocconi, Alessandro; Marra, Antonio; Belli, Carmen; Spallanzani, Andrea; Fassan, Matteo; Lonardi, Sara; Curigliano, Giuseppe; Fucà, Giovanni; Di Bartolomeo, Maria; de Braud, Filippo.
Afiliación
  • Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Loupakis F; Oncology and Hemato-oncology Department, University of Milan, Italy.
  • Randon G; Department of Oncology, Istituto Oncologico Veneto, IRCCS Padua, Italy.
  • Raimondi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Salati M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Trapani D; Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
  • Pagani F; PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Italy.
  • Depetris I; New Drugs Development Division for Innovative Therapies, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
  • Maddalena G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Morano F; Department of Oncology, Istituto Oncologico Veneto, IRCCS Padua, Italy.
  • Corallo S; Department of Oncology, Istituto Oncologico Veneto, IRCCS Padua, Italy.
  • Prisciandaro M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Corti F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Guarini V; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Bocconi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Marra A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Belli C; Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
  • Spallanzani A; New Drugs Development Division for Innovative Therapies, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
  • Fassan M; New Drugs Development Division for Innovative Therapies, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
  • Lonardi S; Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
  • Curigliano G; Surgical Pathology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Fucà G; Department of Oncology, Istituto Oncologico Veneto, IRCCS Padua, Italy.
  • Di Bartolomeo M; Oncology and Hemato-oncology Department, University of Milan, Italy.
  • de Braud F; New Drugs Development Division for Innovative Therapies, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
Oncologist ; 25(9): 803-809, 2020 09.
Article en En | MEDLINE | ID: mdl-32369650

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inestabilidad de Microsatélites / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inestabilidad de Microsatélites / Neoplasias Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido